title: The effect of PTH(1-84) on quality of life in hypoparathyroidism.
abstract: BACKGROUND
  Complaints from hypoparathyroid patients often reflect a reduction in quality of life (QOL), yet few data exist characterizing these complaints or the potential effects of PTH therapy to ameliorate them.
  
  
  OBJECTIVE
  We tested the hypothesis that PTH(1-84) therapy improves QOL in hypoparathyroidism.
  
  
  METHODS
  Fifty-four hypoparathyroid subjects received open-label recombinant human PTH(1-84). Before and during PTH(1-84), subjects completed the RAND 36-Item Health Survey, a measure of health-related QOL covering 8 domains of physical and mental health.
  
  
  RESULTS
  At baseline, subjects scored significantly lower than the normative reference range in all 8 domains (T-scores -1.35 to -0.78; P < 0.001 for all). With PTH(1-84), the total score improved as early as month 1 and remained higher through 1 year (400 ± 200 to 478 ± 230; P = 0.001). The overall mental component summary score improved (204 ± 110 to 247 ± 130; P = 0.001), as did 3 mental health domains (vitality, social functioning, and mental health), all within 1 month (T-scores improving from -1.3 to -0.7, -1.0 to -0.6, and -0.9 to -0.3, respectively; P < 0.05 for all). The overall physical component summary score also increased by 1 month and remained higher at 1 year (196 ± 110 to 231 ± 130; P = 0.003) as did 2 physical health domains (physical functioning and general health: T-scores improving from -0.8 to -0.4, -1.2 to -0.8, respectively; P < 0.01 for both).
  
  
  CONCLUSIONS
  These data suggest that hypoparathyroidism is associated with compromised QOL. Along with improved biochemical control, these results indicate that PTH(1-84) treatment of hypoparathyroidism improves physical and mental functioning.
authors.affiliation: Department of Medicine, Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA.
authors.forename: Natalie E
authors.initials: NE
authors.lastname: Cusano
authors.forename: Mishaela R
authors.initials: MR
authors.lastname: Rubin
authors.forename: Donald J
authors.initials: DJ
authors.lastname: McMahon
authors.forename: Dinaz
authors.initials: D
authors.lastname: Irani
authors.forename: Amanda
authors.initials: A
authors.lastname: Tulley
authors.forename: James
authors.initials: J
authors.lastname: Sliney
authors.forename: John P
authors.initials: JP
authors.lastname: Bilezikian
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007011:Hypoparathyroidism / Q000188:drug therapy* / Q000523:psychology; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000627:therapeutic use*; D011788:Quality of Life; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D010281:Parathyroid Hormone; D011994:Recombinant Proteins